Sort   by:  
 Page size 
GenomicsMutant IDH inhibitors induce lineage differentiation in IDH-mutant Oligodendroglioma II
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant Oligodendroglioma II
PRJNA1084066 | ENA
GenomicsMutant IDH inhibitors induce lineage differentiation in IDH-mutant Oligodendroglioma I
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant Oligodendroglioma I
PRJNA1084024 | ENA
GenomicsMutant IDH inhibitors induce lineage differentiation in IDH-mutant Oligodendroglioma III
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant Oligodendroglioma III
PRJNA1084806 | ENA
TranscriptomicsGenotyping by array of 297 adult-type diffuse gliomas comprise IDH-mutant astrocytomas, IDH-mutant 1p/19q codeleted oligodendrogliomas, and IDH-wildtype glioblastomas
Adult-type diffuse gliomas comprise IDH-mutant astrocytomas, IDH-mutant 1p/19q codeleted oligodendrogliomas (ODG), and IDH-wildtype glioblastomas (GBM). GBM display genome instability, which may result from two genetic events leading to massive chromosome alterations: chromothripsis (CT) and whole-g...
ORGANISM(S): Homo sapiens 
2024-12-24 | E-MTAB-13542 | biostudies-arrayexpress
ProteomicsSequence context specific DNA de-methylation shapes progression of IDH mutant oligodendrogliomas and astrocytomas
Background: Aggressiveness guides treatment in IDH-mutant gliomas. Objective grading of oligodendrogliomas is therefore urgently needed. Material and Methods: 211 primary and recurrent resections from 111 oligodendroglioma patients were collected, complemented with 91 samples for validation. Samples...
ORGANISM(S): Homo sapiens (Human) 
2026-01-19 | PXD070222 | Pride
Lc-ms Oligodendroglioma Idh-mutant 
ClinicalSafety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, and the safety,...
92735 | ecrin-mdr-crc
GenomicsMutant IDH disables p53 tumor suppression [CUT&RUN]
Mutant IDH disables p53 tumor suppression [CUT&RUN]
PRJNA1173479 | ENA
GenomicsMutant IDH disables p53 tumor suppression [RNA-seq]
Mutant IDH disables p53 tumor suppression [RNA-seq]
PRJNA1173573 | ENA
GenomicsModeling therapy sequencing in IDH-mutant glioma reveals that the mutant IDH inhibitor vorasidenib improves chemoradiation response
Modeling therapy sequencing in IDH-mutant glioma reveals that the mutant IDH inhibitor vorasidenib improves chemoradiation response
PRJNA1454117 | ENA
GenomicsMutant IDH modulates suppressive myeloid populations in malignant glioma
Mutant IDH modulates suppressive myeloid populations in malignant glioma
PRJNA1114709 | ENA
Sort   by:  
 Page size